Ezra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.
Manish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.
Stacy L. Moulder, MD, discusses the challenges in drug development for triple-negative breast cancer, specifically in the neoadjuvant setting.
Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.
Hani M. Babiker, MD, shares his advice for community oncologists treating patients with pancreatic cancer.
Lori J. Wirth, MD, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.
Matthew Carlson, MD, discusses his take home message for managing symptoms of chemotherapy in patients with gynecologic cancers.
Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.
Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.
Ezra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Michael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.
Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.
Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with <em>BRAF</em>V600E-mutant metastatic colorectal cancer.
Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.
Mohamad Mohty, MD, PhD, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.
Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis.
Carlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.
Joaquim Bellmunt, MD, PhD, shares his recommendation in how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1, in patients with bladder cancer.
Stephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.
Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.
David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Danny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
Alexander E. Drilon, MD, discusses the prevalence of <em>RET</em> fusions and mutations in patients with cancer, including lung and thyroid cancers.
Joaquim Bellmunt, MD, PhD, discusses the impact of immunotherapy compared to chemotherapy as treatment of patients with bladder cancer.
John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.